Why IMU is a multi multi bagger, page-26100

Imugene expects to have preliminary results from the bile tract cancer expansion trial later this year or early next, depending on how recruitment was going.
I would think due to our discussions with the Cholangiocarcinoma Society we should be recruiting quite well.
As this is a Fast track designation we could see a roll into a Ph2 mid to late next year depending on the data, as bile tract cancer fits the unmet need rules there could be an opportunity to apply for other FDA designations to get it to market quicker.
The bladder cancer expansion is interesting as CG Oncology is already trialing this with an oncolytic virus, IMU must be confident if they are going head to head with them in bladder cancer, particularly when they have some big money to spend on their trial.

DYOR opinion